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1. INTRODUCTION {#jcla22832-sec-0005}
===============

Non--small‐cell lung cancer (NSCLC) is one of the most common malignancies with both high morbidity and mortality rates worldwide, and the fatality rate stands first on the list of cancer‐related deaths.[1](#jcla22832-bib-0001){ref-type="ref"} Lung adenocarcinoma is one of the most common histological types in NSCLC. Due to the lack of reliable biomarkers for early diagnosis, recurrence, and metastasis, its prognosis is still poor.[2](#jcla22832-bib-0002){ref-type="ref"} The biological characteristics of the metabolic tumor environment have important influence on proliferation, invasion, migration, adhesion, and neovascularization of the tumor. The tumor stroma thus strongly influences recurrence and formation of metastasis. Most NSCLC are characterized by fibrous connective tissue proliferation,[3](#jcla22832-bib-0003){ref-type="ref"} and the stromal changes are accompanied by fibroblast differentiation into cancer‐associated fibroblasts (CAFs), which alter the extracellular matrix components in tumor areas and influence neovascularization,[4](#jcla22832-bib-0004){ref-type="ref"} and consequently contribute to the growth, invasion and metastasis of tumors. Regarding molecular markers, α‐smooth muscle actin (α‐SMA), fibroblast activation protein (FAP), vimentin, etc have been previously used to identify CAFs,[5](#jcla22832-bib-0005){ref-type="ref"} and the filamentous protein α‐SMA as the most widely accepted one.[6](#jcla22832-bib-0006){ref-type="ref"}, [7](#jcla22832-bib-0007){ref-type="ref"}

Growth and metastasis of lung cancer depends on the formation of blood vessels.[11](#jcla22832-bib-0011){ref-type="ref"} Angiogenesis is an important pathophysiological process of occurrence, development, and progression of the tumor. Quantitative indicators include microvascular density (MVD) and levels of vascular endothelial growth factors (VEGF) in the serum. MVD not only reflects the process of angiogenesis, but also predicts tumor growth, metastasis, and recurrence.[12](#jcla22832-bib-0012){ref-type="ref"} CD34 is a marker of mature endothelial cells and is applied for MVD evaluation. LVD is another critical parameter for predicting disease outcome and it has been used as a major indicator for the treatment regimen. D2‐40, a sialic acid glycoprotein, binds to the mucous membrane glycoprotein of the lymphatic endothelial cells and enables distinction between lymphatic and blood vessels.[13](#jcla22832-bib-0013){ref-type="ref"}

To further understand the NSCLC subgroup and prognostic indicators associated with early onset, development, and metastasis, we analyzed the association between abundance of CAFs in lung adenocarcinoma and MVD and LVD, and correlate these parameters with patient survival. These findings may aid in developing novel therapeutic strategies to tackle this devastating disease.

2. MATERIAL AND METHODS {#jcla22832-sec-0006}
=======================

2.1. Patients and tissue specimens {#jcla22832-sec-0007}
----------------------------------

A total of 125 formalin‐fixed and paraffin‐embedded tumor samples from patients who underwent curative surgical resection from stage I‐III lung adenocarcinoma at the Department of Thoracic Surgery in the Qingdao Municipal Hospital from January 1, 2010, to June 31, 2011, were selected. All patients had definite pathological diagnosis after surgery. Patients who received adjuvant therapy were excluded. Thirty‐two patients were lost during the follow‐up study. Ninety‐three patients were finally enrolled into this study, including 60 male patients and 33 female patients. Among these patients, 11 cases were the central‐type lung adenocarcinoma and 82 cases were peripheral lung adenocarcinoma. Clinical records of the patients, including name, gender, age, smoking history, tumor stage, differentiated degree, and the condition of the follow‐up, are fully documented according to the standard of the Union for International Cancer Control \[<https://www.uicc.org/resources/tnm>\]. Written informed consent was obtained from all patients. The study was approved by the Ethical Committee of Qingdao Municipal Hospital.

2.2. Immunohistochemistry {#jcla22832-sec-0008}
-------------------------

Five micrometer sections were stained with α‐SMA monoclonal antibody (1:100, Maixin, Shanghai) for immunohistochemical evaluation of CAFs. Microvessels were stained with CD34 (1:100, Maixin, Shanghai), and lymphatic vessels were assessed by D2‐40 staining (1:50, Zhongshanjinqiao, Beijing). Immunohistochemical staining was proceeded as follows: After deparaffinization and dehydration, sections were boiled in Tris‐EDTA buffer (10 mmol/L Tris Base, 1 mmol/L EDTA Solution, 0.05% Tween 20, pH 9.0) for antigen unmasking, followed by extensive washing with PBS. Sections were subsequently incubated with 3% H~2~O~2~ for 10 minutes, and then rinsed with PBS for three times. Sections were blocked with 2% goat serum albumin in PBS for 20 minutes and incubated with anti‐α‐SMA, anti‐D2‐40 or anti‐CD34 antibodies for 1 hour at 37°C. After three times of washing with PBS, sections were incubated with anti‐mouse or anti‐rabbit antibodies (Envision plus, Dako) for 10 minutes at 37°C. After washing with PBS, peroxidase activity was detected with diaminobenzidine under microscopy. Subsequently, the specimens were counterstained with hematoxylin and dehydrated, hyalinized and embedded. Each section was independently evaluated by two pathological experts who did not understand the clinical status of the patients.

2.3. CAF immunohistochemical scoring {#jcla22832-sec-0009}
------------------------------------

α‐SMA‐positive stained tissues were graded as CAFs‐rich and CAFs‐poor groups according to CAFs staining density as previously described.[14](#jcla22832-bib-0014){ref-type="ref"}, [15](#jcla22832-bib-0015){ref-type="ref"} Briefly, the most densely populated staining areas known as hot spot areas were selected and evaluated under microscopy. The α‐SMA positivity was calculated as percentage of α‐SMA‐positive cell numbers/total cell count. A value ≥40% was considered high CAFs group, and \<40% was defined as CAFs‐poor group.

2.4. Quantification of MVD {#jcla22832-sec-0010}
--------------------------

The evaluation method for MVD followed Wang[16](#jcla22832-bib-0016){ref-type="ref"}: Vessel hot spot regions were identified under 40× magnifications and then 400× magnification was applied for counting microvessels in three separate hot spots and the average was calculated and expressed as mean.

2.5. Quantification of LVD {#jcla22832-sec-0011}
--------------------------

LVD was evaluated as described by Weidner et al[17](#jcla22832-bib-0017){ref-type="ref"}: The lumen in ribbon‐shaped or lacuna‐shaped structures, formed by endothelial cells and positively stained by D2‐40, is identified as lymphatic vessels. Hot spot regions were selected under 40× and 100× magnification. The density of lymph‐vessels was evaluated under 400× magnification and the average numbers from five selected hot spots were calculated and expressed as mean.

2.6. Follow‐up {#jcla22832-sec-0012}
--------------

The follow‐up information was collected until death or disease progression. A routine protocol including detailed inquiry of medical history and radiological examination was preceded over the course of the follow‐up period.

2.7. Statistical analyses {#jcla22832-sec-0013}
-------------------------

Statistical package SPSS version 20.0 (SPSS Inc. Chicago, IL, USA) was used for data analyses. Pearson\'s chi‐square test and logistic regression were used for exploring the correlation between clinical data and immunohistochemical results. Kaplan‐Meier method was employed to calculate the survival rate. Difference between groups was done by the log‐rank test. Cox proportional hazards model was used to predict survival rate by multivariate analysis, and *P*‐value \<0.05 was considered statistically significant.

3. RESULTS {#jcla22832-sec-0014}
==========

3.1. α‐SMA expression and CAFs density in lung adenocarcinoma {#jcla22832-sec-0015}
-------------------------------------------------------------

α‐SMA‐positive staining was mainly detected in tumor stroma, indicating involvement of CAFs in tumor pathogenesis. Out of the 93 cases, 62 were defined as high CAFs group (Figure [1](#jcla22832-fig-0001){ref-type="fig"}A) and 31 were low CAFs expressing (Figure [1](#jcla22832-fig-0001){ref-type="fig"}B).

![A, α‐SMA staining of lung adenocarcinoma, 400× magnification (CAFs‐rich group); B, α‐SMA staining of lung adenocarcinoma, 400× magnification (CAFs‐poor group); C, CD34 staining of lung adenocarcinoma, 400× magnification (CAFs‐rich group); D, CD34 staining of lung adenocarcinoma, 400× magnification (CAFs‐poor group); E, D2‐40 staining of lung adenocarcinoma, 400× magnification (CAFs‐rich group); F, D2‐40 staining of lung adenocarcinoma, 400× magnification (CAFs‐poor group)](JCLA-33-e22832-g001){#jcla22832-fig-0001}

3.2. CAFs density and MVD, LVD {#jcla22832-sec-0016}
------------------------------

Intratumoral microvessel density was quantified by measuring CD34‐positive staining which was mainly detected in vascular endothelial cell membrane and a lower degree in the cytoplasm. The correlation was evaluated by Pearson\'s chi‐squared test. MVD was significantly higher in CAFs‐rich group than in the CAFs‐poor group (Figure [1](#jcla22832-fig-0001){ref-type="fig"}C; *P* = 0.02, Table [1](#jcla22832-tbl-0001){ref-type="table"}A), indicating involvement of CAFs in angiogenesis.

###### 

\(A\) Correlation between CAFs density and MVD. (B) Correlation between CAFs density and LVD

               α‐SMA   *χ* ^2^   *P*      
  ------------ ------- --------- -------- -------
  \(A\) CD34                              
  Negative     24      33        5.099    0.020
  Positive     7       29                 
  \(B\) D240                              
  Negative     19      12        16.355   0.000
  Positive     12      50                 

CAFs, cancer‐associated fibroblasts; LVD, lymphatic vessel density; MVD, microvessel density.
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The lymphatic vessel areas with lumen were quantified via D2‐40 staining. LVD area was significantly higher in CAFs‐rich group than in the CAFs‐poor group (Figure [1](#jcla22832-fig-0001){ref-type="fig"}D; *P* \< 0.001, Table [1](#jcla22832-tbl-0001){ref-type="table"}B), suggesting a close relationship between CAFs and lymphangiogenesis.

3.3. CAFs density, MVD, LVD and clinicopathological features in lung adenocarcinoma {#jcla22832-sec-0017}
-----------------------------------------------------------------------------------

Correlations between CAFs abundance, MVD, LVD, and other clinicopathological characteristics were determined using Pearson\'s chi‐squared test and logistic regression. CAFs density, MVD, and LVD are significantly correlating with age, tumor size, degree of differentiated, clinical stages, and lymph node metastasis (*P* \< 0.05), but they were not affected by parameters of gender, tumor location, and smoking history (*P* \> 0.05) (Table [2](#jcla22832-tbl-0002){ref-type="table"}).

###### 

CAFs, MVD, and LVD in 93 patients with lung adenocarcinoma and their correlation with clinical pathological variables

                          N    CAFs    *P*                       HR (95%CI)              MVD                        *P*     HR (95%CI)                LVD   *P*     HR (95%CI)
  ----------------------- ---- ------- ------------------------- ----------------------- -------------------------- ------- ------------------------- ----- ------- -----------------------
  Gender                                                                                                                                                            
  Men                     60           1.000                     1.000 (0.406‐2.462)                                0.219   1.759 (0.714‐4.331)             0.170   1.864 (0.765‐4.538)
  Women                   33                                                                                                                                        
  Age                                                                                                                                                               
  ≥60                     55           0.007                     1.065 (1.017‐1.114)                                0.000   1.138 (1.071‐1.209)             0.013   1.059 (1.012‐1.107)
  \<60                    38                                                                                                                                        
  Location                                                                                                                                                          
  Central                 11           0.821                     1.164 (0.313‐4.323)                                0.626   0.729 (0.205‐2.592 )            0.821   1.164 (0.313‐4.323)
  Peripheral              82                                                                                                                                        
  Diameter                                                                                                                                                          
  \>3 cm                  65           0.000                     12.273 (4.315‐34.906)                              0.001   14.258 (3.124‐65.083)           0.000   16.500 (5.554‐49.021)
  ≤3 cm                   28                                                                                                                                        
  Differentiation grade                                                                                                                                             
  High                    18           0.007                     1                                                  0.001   1                               0.014   1
  Medium                  53   0.048   3.056 (1.012‐9.226)       0.998                   637687425\.543 (0.000‐)    0.190   2.062 (0.698‐6.091)                     
  Poor                    22   0.002   15.714 (2.772‐89.098)     0.998                   33924971038.902 (0.000‐)   0.004   26.250 (2.877‐239.537)                  
  TNM staging                                                                                                                                                       
  I                       27           0.000                     1                                                  0.000   1                               0.000   1
  II                      35   0.000   9.643 (3.000‐30.995)      0.179                   3.125 (0.593‐16.459)       0.000   10.111 (3.100‐32.980)                   
  IIIa                    19   0.000   15.238 (3.387‐68.553)     0.000                   46.875 (7.640‐287.595)     0.000   63.00 (6.921‐573.503)                   
  IIIb                    12   0.998   4615642473.783 (0.000‐)   0.998                   20193435809.473 (0.000‐)   0.998   5654162030.960 (0.000‐)                 
  Lymphatic metastasis                                                                                                                                              
  With                    58           0.005                     3.665 (1.482‐9.066)                                0.001   14.258 (3.124‐65.083)           0.001   4.552 (1.815‐11.419)
  Without                 35                                                                                                                                        
  Smoking history                                                                                                                                                   
  With                    47           0.558                     0.772 (0.325‐1.834)                                0.731   1.158 (0.502‐2.669)             0.306   0.635 (0.266‐1.516)
  Without                 46                                                                                                                                        

CAFs, cancer‐associated fibroblasts; LVD, lymphatic vessel density; MVD, microvessel density.
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3.4. CAFs density and 3‐year survival and overall survival {#jcla22832-sec-0018}
----------------------------------------------------------

Three‐year survival of CAFs‐poor group was 64.5%, which is significantly higher than in CAFs‐rich group (41.9%) (Table [3](#jcla22832-tbl-0003){ref-type="table"}). Kaplan‐Meier analyses showed that age, clinical stage, CAFs density, MVD, LVD, tumor size, degree of differentiation, and lymph node metastasis all had impact on the overall survival (OS) (*P* \< 0.001; *P* \< 0.001; *P* \< 0.05; *P* \< 0.001; *P* \< 0.05; *P* \< 0.001; *P* \< 0.001; *P* \< 0.001, respectively) (Figure [2](#jcla22832-fig-0002){ref-type="fig"}), while gender, smoking history, and tumor location had little influence (*P* = 0.086; 0.096; 0.843, respectively). Cox multifactor analysis identified clinical stage as an independent prognostic factor in lung adenocarcinoma (*P* \< 0.05).

###### 

Correlation between OS and CAFs proportion in 93 patients with lung adenocarcinoma

  CAFs   Overall survival   *χ* ^2^   *P*     
  ------ ------------------ --------- ------- -------
  Poor   60                 33        9.524   0.002
  Rich   39                 54                

CAFs, cancer‐associated fibroblasts.

John Wiley & Sons, Ltd

![Correlation between OS and each parameter. A, Correlation between OS and α‐SMA; B, Correlation between OS and clinical stage; C, Correlation between OS and MVD; D, Correlation between OS and patient\'s age (y); E, Correlation between OS and LVD; F, Correlation between OS and tumor diameter; G, Correlation between OS and cancer differentiation; H, Correlation between OS and smoking; I, Correlation between OS and gender; J, Correlation between OS and tumor location; K, Correlation between OS and lymphatic metastasis](JCLA-33-e22832-g002){#jcla22832-fig-0002}

4. DISCUSSION {#jcla22832-sec-0019}
=============

It is well known today that development and progression of malignant tumors rely on the tumor microenvironment. Although the clinical stage is often an independent prognostic factor in OS, the different disease outcome in patients with the same pathological stage significantly depends on the diversity of tumor behaviors. During tumor development, tumor stroma not only supplies nutrition to support tumor cell proliferation, but also offers a platform for tumor invasion and metastasis through angiogenesis and lymphangiogenesis. As a result, components in the tumor stroma may be used as therapeutic targets to reverse the malignant transformation. Specific cells in the stroma such as CAFs may be used for anti‐tumor therapy.[18](#jcla22832-bib-0018){ref-type="ref"}

Previous reports show that CAFs play a crucial role in the progression of lung adenocarcinoma; they are significantly different from normal fibroblasts. These cells express high levels of α‐SMA and show increased proliferative capacity compared to normal fibroblasts.[19](#jcla22832-bib-0019){ref-type="ref"} These specific characteristics are often closely associated with malignancy of the primary tumor that CAFs support.[20](#jcla22832-bib-0020){ref-type="ref"}, [21](#jcla22832-bib-0021){ref-type="ref"} In studies of esophageal, oral cancer, and other malignant diseases, CAFs density show a prognostic value and  is strongly associated with increased mortality.[22](#jcla22832-bib-0022){ref-type="ref"} MVD and LVD are important indicators to reflect tumor metastatic activity and show close relationship with progression of lung adenocarcinoma in the current as well as in previous studies.[23](#jcla22832-bib-0023){ref-type="ref"}, [24](#jcla22832-bib-0024){ref-type="ref"} Empirical evidence supports that MVD and LVD are closely related to lymph node metastasis, distant metastasis, differentiation degree, and clinical stage in lung adenocarcinoma and CAF density can be considered as a novel biomarker for disease prognosis in patients with lung squamous cell carcinoma.[25](#jcla22832-bib-0025){ref-type="ref"}

Pathological evaluation showed that in 93 patients with lung adenocarcinoma, 62 cases are CAFs rich (66.7%), and 31 patients (33.3%) are CAFs poor. Pearson\'s correlation analysis indicated MVD and LVD were significantly higher in the CAFs‐rich patients (*P* \< 0.05), indicating a positive association between CAFs abundance and MVD and LVD. The direct correlation between MVD and LVD (*P* \< 0.05) further demonstrated a close relationship of angiogenesis and lymphangiogenesis. In addition, we showed that CAFs, MVD, and LVD in lung adenocarcinoma significantly correlate with tumor size, degree of differentiation, clinical stages, and lymph node metastasis (*P* \< 0.05). These results further demonstrated that the tumor microenvironment is essential for supporting the progression of lung adenocarcinoma. The 3‐year survival rate of CAFs‐poor (64.5%) was significantly higher than from the CAFs‐rich group (41.9%). LVD is an indicator of favorable survival.[26](#jcla22832-bib-0026){ref-type="ref"} Additionally, age, clinical stage, MVD, the degree of differentiation, and lymph node metastasis were all found to affect the OS of lung adenocarcinoma patients. These data further emphasize the complexity of the disease. Interestingly, among all analyzed factors, clinical staging was the only parameter that showed an independent prognostic factor for OS in patients with lung adenocarcinoma.

5. CONCLUSIONS {#jcla22832-sec-0020}
==============

The abundance of CFA, MVD, and LVD is negatively correlated with the prognosis of patients with lung adenocarcinoma. These results demonstrate the important roles of microenvironment in the progression of lung adenocarcinoma and provide useful data to support personalized disease therapy.
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